ReviewVascular health and risk management2009
Arterial stiffness, hypertension, and rational use of nebivolol.
Review in Vascular health and risk management, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 83 citations in OpenAlex.
- Differential Metabolic Effects of Beta-Blockers: an Updated Systematic Review of Nebivolol.Current hypertension reports · 2017Pooled it
- Effect of Amlodipine/Valsartan Versus Nebivolol/Valsartan Fixed Dose Combinations on Peripheral and Central Blood Pressure.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2018Trial
- The effect of low-dose carvedilol, nebivolol, and metoprolol on central arterial pressure and its determinants: a randomized clinical trial.Journal of clinical hypertension (Greenwich, Conn.) · 2013Trial
- Comparative effectiveness of a fixed-dose combination of losartan + HCTZ versus bisoprolol + HCTZ in patients with moderate-to-severe hypertension: results of the 6-month ELIZA trial.Vascular health and risk management · 2013Trial
- Cardiovascular Magnetic Resonance Elastography: Current Evidence, Challenges, and Future Perspectives.Diagnostics (Basel, Switzerland) · 2026Review
- Arterial stiffness and vascular aging: mechanisms, prevention, and therapy.Signal transduction and targeted therapy · 2025Review
- Beta Blockers as Primary and Secondary Prevention for Aortic Dissections in Nonsyndromic Patients With Hypertension.Journal of the American Heart Association · 2025Article
- Titin is a new factor regulating arterial stiffness through vascular smooth muscle cell tone in male rats.Physiological reports · 2025Article
- Aortopathies: From Etiology to the Role of Arterial Stiffness.Journal of clinical medicine · 2023Review
- Effect of Different Classes of Antihypertensive Drugs on Arterial Stiffness.Current hypertension reports · 2023Review
- Integrating Ultrasound-Derived Carotid Artery Stiffness in the Assessment of Cardiovascular Risk.Cardiology & vascular research (Wilmington, Del.) · 2023Article
- Nocturia is associated with stiffer central artery and more likely development of major adverse cardiovascular events in men.Frontiers in urology · 2023Article
- Mineralocorticoid receptor antagonist treatment improved arterial stiffness in patients with primary aldosteronism: a cohort study compared with adrenalectomy.Therapeutic advances in chronic disease · 2023Article
- Age and Blood Pressure Contribute to Aortic Cell and Tissue Stiffness Through Distinct Mechanisms.Hypertension (Dallas, Tex. : 1979) · 2022Article
- Degradation of Premature-miR-181b by the Translin/Trax RNase Increases Vascular Smooth Muscle Cell Stiffness.Hypertension (Dallas, Tex. : 1979) · 2021Article
- Heightened Stress Reactivity in Response to an Attachment Related Stressor in Patients With Medically Treated Primary Hypertension.Frontiers in psychiatry · 2021Article
- Deletion of the microRNA-degrading nuclease, translin/trax, prevents pathogenic vascular stiffness.American journal of physiology. Heart and circulatory physiology · 2019Article
- Effect of Nebivolol and Olmesartan on 24-Hour Brachial and Aortic Blood Pressure in the Acute Stage of Ischemic Stroke.International journal of hypertension · 2019Article
- Cardiovascular magnetic resonance elastography: A review.NMR in biomedicine · 2018Review
- Role of nebivolol in the control and management of central aortic blood pressure in hypertensive patients.Journal of human hypertension · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Arterial stiffness plays a key role in the pathophysiology of the cardiovascular system. Some indices of arterial stiffness (pulse wave velocity, augmentation index, characteristics of central blood pressure waveform) may be presently calculated and evaluated in the clinical setting. Age and blood pressure are the two major clinical determinants of increased arterial stiffness, while molecular determinants of arterial stiffness are related to fibrotic components of the extracellular matrix, mainly elastin, collagen and fibronectin. Increased arterial stiffness has been consistently observed in conditions such as hypertension, dyslipidemia and diabetes. Arterial stiffness evaluated by means of carotid-femoral pulse wave velocity yielded prognostic significance beyond and above traditional risk factors. A more favorable effect of calcium channel blockers, diuretics and ACE inhibitors compared with beta-blockers on indices of arterial stiffness was observed in several studies. It is conceivable that newer beta-blockers with additional vasodilating properties, such as nebivolol, which has favorable effects on carbohydrate and lipid metabolism, as well as on endothelial function and on oxidative stress, may have favorable effects on arterial stiffness, compared with atenolol. In fact, in recent studies, nebivolol was demonstrated to improve artery stiffness to a greater extent than older beta-blockers. Because endothelial dysfunction and increased arterial stiffness play an important role in the early atherosclerotic processes and are associated with poor outcomes and increased mortality, independently of blood pressure, the ability of nebivolol to enhance release of endothelium-derived nitric oxide, and consequently improve endothelial function and arterial stiffness, may have significant clinical implications for the use of this agent in the treatment of hypertension and cardiovascular diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.